UWM
CPRX

Urban Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Urban Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$9K Buy
+1,253
New +$9.19K 0.03% 206

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Urban Wealth Management's CPRX Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2022: 1,253 shares worth $9K. The stake represents 0.03% of the portfolio and ranks #206 among its holdings.

189 funds tracked by Wall St. Rank hold CPRX as of Q2 2022.

  • Urban Wealth Management held 1,253 shares of Catalyst Pharmaceutical worth $9K as of Q2 2022.
  • Catalyst Pharmaceutical was a new Urban Wealth Management position in Q2 2022.
  • Catalyst Pharmaceutical made up 0.03% of Urban Wealth Management's portfolio in Q2 2022, its #206 holding.
  • 189 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.